---
title: "Choosing a Vendor for Compliance-Driven QA (Regulated Industries)"
keywords: "compliance QA vendor, regulated industry software testing, IEC 62304 QA, GxP validation testing, audit-ready test evidence, ISO 13485 software testing"
buyer_stage: "Decision"
target_persona: "Compliance Officer"
---

# Choosing a Vendor for Compliance-Driven QA (Regulated Industries)

<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "Article",
  "headline": "Choosing a Vendor for Compliance-Driven QA (Regulated Industries)",
  "description": "A compliance officer's framework for selecting a QA and testing vendor in regulated industries, covering traceability, validation documentation, audit trails, and what auditors actually check before accepting third-party test evidence.",
  "author": {"@type": "Organization", "name": "Manifera", "url": "https://www.manifera.com/"},
  "publisher": {"@type": "Organization", "name": "Manifera", "url": "https://www.manifera.com/"},
  "datePublished": "2026-08-18",
  "mainEntityOfPage": {"@type": "WebPage", "@id": "https://www.manifera.com/blog/choosing-a-vendor-for-compliance-driven-qa-regulated-industries"}
}
</script>

An auditor asks your QA vendor to produce the signed test evidence for a release from eight months ago, tied to the specific requirement it verifies, with the tester's identity and the approver's sign-off intact. Can they produce it in an afternoon, or does someone start reconstructing a paper trail from Slack messages and a shared spreadsheet? That single question is the real audit for a compliance-driven QA vendor, and most vendor demos never get anywhere near it.

If you are evaluating QA vendors under IEC 62304 for medical device software, GxP for pharma-adjacent systems, ISO 13485 for a quality management system, DORA for financial-sector ICT resilience, or PCI-DSS for payment processing, you already know that "the software works" is not the deliverable — the deliverable is proof that it works, produced in a form a third-party auditor or regulator will accept without argument. That distinction changes almost everything about how you evaluate a vendor: not their bug-finding ability, but their evidence-producing discipline. This article works through the specific criteria that separate a vendor who can pass a functional QA engagement from one who can survive an FDA inspection, a notified-body audit, or a DORA resilience review.

## Traceability Matrices Are the Deliverable, Not a Byproduct

In regulated QA, the requirements traceability matrix — the document mapping every regulatory or user requirement to the specific test case that verifies it, and every test case to its execution evidence — is not paperwork generated after the fact. It is the artifact the entire engagement exists to produce. A vendor that treats traceability as something to backfill before an audit rather than something built into the test management tool from day one will produce matrices with gaps: requirements with no linked test, tests with no linked requirement, or worse, tests that were re-run after a code change without the matrix being updated to reflect it.

Ask any shortlisted vendor to show you a live traceability matrix from an existing regulated client (redacted, but structurally intact) rather than a template. Look specifically at how they handle requirement changes mid-project — a mature vendor's tooling flags every test case whose linked requirement changed and forces a re-verification decision, rather than letting a stale test silently continue to "pass." Tools like Jama Connect, Polarion, or even a disciplined TestRail/Jira integration can support this, but the tool matters less than whether the vendor's QA process treats traceability gaps as a defect in their own work, not yours.

Also probe how the vendor handles bidirectional traceability specifically, not just forward mapping from requirement to test. A regulator reviewing a design history file will often start from a defect found in the field and trace backward: which requirement did this relate to, which test was supposed to catch it, and why didn't it. If a vendor's matrix only supports forward tracing — requirement to test — and cannot answer "show me every test case touching this requirement" in minutes rather than hours of manual cross-referencing, the tooling is not actually fit for audit defense, regardless of how complete the forward mapping looks on a given day.

## Segregation of Duties Is a Structural Requirement, Not a Policy Statement

GxP, IEC 62304, and most financial-services audit frameworks require segregation of duties between the person who writes code, the person who tests it, and the person who approves the test result for release. This is not satisfied by a written policy — it has to be visible in the vendor's actual team structure and system access logs. If a single engineer at the vendor can write a feature, execute its verification test, and mark it passed with no independent review, the evidence that engagement produces will not survive a serious audit, regardless of how thorough the testing itself was.

Verify this concretely: ask for the vendor's RACI on a recent regulated engagement, and cross-check it against their access control setup in the test management and version control systems. A vendor with genuine segregation of duties can show you role-based permissions where testers cannot merge code and developers cannot approve their own test evidence — enforced by the tooling, not just the org chart. This is also where smaller QA shops most often fail: segregation of duties requires enough headcount that the same three people are not wearing every hat, which is a real constraint on vendor size for this specific work.

## Audit Trail Integrity: What "Signed" Actually Needs to Mean

Regulators and auditors do not just want to know a test passed — they want an immutable, timestamped, attributable record of who executed it, when, against which software version, with what result, and who approved it for release. Electronic signature requirements under 21 CFR Part 11 (for FDA-regulated software) or equivalent EU frameworks mean the vendor's test management system needs audit-trail features that log every edit to a test record, not just the final state. A spreadsheet-based test log, however well organized, cannot produce this — it has no tamper-evidence and no enforced attribution.

Ask specifically how the vendor's system handles a corrected test result: if a tester marks something "pass" in error and corrects it to "fail" the next day, does the system retain both entries with timestamps and reasons, or does it silently overwrite? The former is audit-defensible; the latter is a finding waiting to happen. This is a genuinely different skill set from general QA — a vendor excellent at exploratory testing and bug-hunting for a consumer app may have never built a Part 11-compliant audit trail, and that gap does not show up in a standard technical interview.

Also check who controls the identity layer behind the signature. Part 11 requires that an electronic signature be uniquely linked to one individual and not reassignable — shared logins, generic "QA Team" accounts, or a project manager entering results on behalf of a tester all break this requirement even if every other part of the process looks compliant. A vendor with mature regulated-industry practice will have individual, non-shared credentials for every tester as a non-negotiable baseline, enforced by their own IT policy rather than left to project-level discretion.

## Domain-Specific Standards Fluency Versus General Test Automation Skill

A vendor can be excellent at Selenium, Playwright, or Cypress automation and still be the wrong choice if they have never validated software under IEC 62304's Class B or C risk categorization, never written an Installation/Operational/Performance Qualification (IQ/OQ/PQ) protocol for a GxP system, or never mapped test coverage to ISO 13485 design controls. These are learnable skills, but learning them on your engagement, on your audit timeline, is an expensive way to find out a vendor is starting from zero.

Screen for this directly: ask candidate vendors to walk through, in specific terms, how they scoped risk-based testing depth on a prior regulated engagement — a vendor with real experience will describe how they classified software safety risk (e.g., IEC 62304 Class A/B/C) and adjusted verification rigor accordingly, rather than applying the same test depth uniformly. A vendor without this experience will describe generic test coverage percentages instead, which is a tell.

## What Auditors Actually Reject, Based on Real Findings

The most common reasons auditors reject third-party test evidence are mundane and repeatable: test cases with no linked requirement, evidence with no verifiable tester identity, environment configurations not documented alongside the test run (so the test cannot be proven representative of production), and re-tests after code changes with no re-verification record. A vendor's sales team will tell you they are "audit-ready." Ask instead for a redacted example of an actual finding from a past audit or inspection, and how they remediated it — a vendor with real regulated-industry mileage has findings in their history, because every vendor operating in this space long enough does. One with a spotless record and no specifics to share has likely not been through a rigorous inspection at all.

## Data Residency, Access Control, and the Cost of Getting It Wrong

For fintech under DORA or PCI-DSS, and for healthtech handling patient data, where the vendor's testers physically sit and what data they can access during testing matters as much as their process discipline. Test environments using real or realistic production-like data introduce a second compliance question layered on top of QA quality: is test data masked or synthetic, is access logged and time-bound, and does the vendor's own security posture (SOC 2, ISO 27001) hold up under your own vendor risk assessment. A QA vendor that is excellent at traceability but weak on data handling controls creates a different kind of audit exposure — one your compliance function, not just your QA function, will own.

This is also where offshore delivery models earn extra scrutiny, not automatic disqualification. A vendor operating across jurisdictions needs a documented data processing agreement, clarity on where test data physically resides during an engagement, and, for healthtech specifically, an honest answer on whether synthetic or de-identified data is used in place of real patient records during verification testing. None of this rules out an offshore or nearshore QA partner — plenty of regulated engagements run successfully with distributed teams — but it does mean the data handling conversation needs to happen explicitly in the vendor selection process, not get assumed away because the process documentation elsewhere looks strong.

## Cost Structure: What Compliance-Grade QA Actually Costs Versus Generic Testing

Compliance-driven QA costs more than generic functional testing, typically 20-40% more per test cycle once documentation, traceability maintenance, and segregation-of-duties overhead are priced in — and vendors who quote at parity with generic QA rates are usually not pricing in the actual documentation burden, which shows up later as scope creep or corner-cutting under deadline pressure. Budget for this upfront rather than treating validation documentation as a line item that gets trimmed when a release date slips, since that is precisely the corner an auditor will find cut.

## Making the Final Call

The right compliance-driven QA vendor is not necessarily the one with the deepest general test automation bench — it is the one whose tooling, team structure, and documentation habits already produce audit-defensible evidence as a natural byproduct of doing the work, not as a scramble before an inspection. Weight your evaluation toward traceability discipline, segregation of duties, and audit trail integrity over raw test throughput; a vendor that finds fewer bugs but produces bulletproof evidence is usually the safer choice in a regulated context, though for lower-risk software components within the same product, a faster, less document-heavy QA approach can still be the right call to avoid over-engineering compliance overhead where it isn't required.

Manifera's QA and testing practice works within regulated software delivery contexts where traceability and audit-ready documentation are part of the deliverable, not an afterthought. If you're scoping a compliance-driven QA engagement, our [custom software development](https://www.manifera.com/services/custom-software-development/) team can walk through how validation documentation gets built into the delivery process from day one.

## Risk-Based Test Depth: How Classification Should Actually Change the Work

IEC 62304's software safety classification (Class A: no injury possible, Class B: non-serious injury possible, Class C: death or serious injury possible) should visibly change the QA vendor's test depth, not just the paperwork wrapped around it. Class C components warrant unit test coverage typically at or above 90-100% for safety-critical code paths, full boundary and equivalence-class testing on every input, and independent code review beyond the original developer before any test is marked passed. Class A components — a settings screen with no clinical impact, for example — can reasonably run at standard functional test coverage (60-80%) without the same verification overhead, and a vendor applying Class C rigor uniformly across a whole codebase is usually padding hours, not protecting patients.

Ask a shortlisted vendor to walk through how they'd classify three or four specific features from your actual product and what test depth follows from each classification — a vendor with real IEC 62304 mileage will give different, justified answers per feature rather than a single blanket coverage target. The same logic applies under GxP's risk-based validation approach (ICH Q9) and DORA's criticality tiering for financial-sector ICT systems: the standard exists precisely so testing effort scales with actual patient or financial risk, not with a vendor's default process template.

Budget conversations should follow this classification too — quoting the same per-test-case rate across Class A and Class C work signals the vendor hasn't actually built risk-differentiated pricing into their model.

## Frequently Asked Questions

### What makes QA "compliance-driven" versus standard functional testing?
Compliance-driven QA produces auditable evidence as its primary deliverable — a traceability matrix linking every requirement to test evidence, segregation of duties between developer and approver, and an immutable audit trail — rather than simply confirming the software behaves correctly. Standard functional testing optimizes for finding defects; compliance-driven QA optimizes for defensible proof of verification.

### Which standards matter most when vetting a QA vendor for a regulated industry?
It depends on your sector: medical device and health software typically need IEC 62304 and ISO 13485 fluency, pharma-adjacent systems need GxP and 21 CFR Part 11 experience, financial services need DORA and PCI-DSS awareness. Ask any vendor which of these they have direct engagement experience with rather than general familiarity, since the practical differences in documentation depth between them are significant.

### How much more does compliance-grade QA cost compared to regular QA?
Expect 20-40% higher cost per test cycle once traceability maintenance, validation documentation, and segregation-of-duties overhead are priced in correctly. Vendors quoting at parity with generic QA rates are usually underpricing the documentation burden, which tends to surface later as corner-cutting under deadline pressure.

### Can a small QA vendor properly implement segregation of duties?
It is difficult below a certain team size, because segregation of duties requires enough distinct people that the same individual is not writing, testing, and approving the same work. Verify this concretely by reviewing a vendor's RACI and system access controls on a past regulated engagement rather than accepting a policy statement at face value.

### What is the single biggest reason auditors reject third-party test evidence?
The most common rejection reason is a broken or incomplete traceability link — a test case with no linked requirement, or a re-test after a code change with no updated verification record. Environment documentation gaps and unverifiable tester identity are the next most common findings in practice.

### (Scenario: evaluating an offshore or nearshore QA vendor for an FDA or EU MDR-regulated product) Does offshore delivery automatically disqualify a vendor from compliance-driven QA work?
No — regulators care about evidence integrity and data handling, not the tester's physical location. What matters is a documented data processing agreement, individual non-shared credentials for every tester regardless of where they sit, and an honest answer on whether synthetic or de-identified data is used during verification testing rather than real patient or financial records.

### (Scenario: a product's software safety classification changes mid-engagement, e.g. Class B reclassified to Class C) What happens to test evidence produced under the earlier classification?
Existing evidence doesn't automatically become invalid, but it needs a documented gap analysis against the new classification's higher verification requirements, and any test that no longer meets the new depth threshold needs re-execution with the evidence trail showing why. A vendor's traceability tooling should flag every affected test case automatically rather than requiring a manual re-audit of the entire suite.

### (Scenario: a vendor proposes AI-assisted test case generation for a regulated engagement) Is AI-generated test evidence acceptable to auditors?
Auditors generally accept AI-assisted test case generation as a productivity tool, but the human accountability chain still has to be intact — a qualified person must review and approve each generated test case against the linked requirement before execution, and the audit trail needs to show that review occurred, not just that a tool produced output. Treat AI-generated tests as a draft requiring the same sign-off rigor as a human-written one, not a shortcut around segregation of duties.

### (Scenario: a product must satisfy both FDA and EU MDR requirements simultaneously) Does test evidence need to be duplicated for each regulatory regime?
Often the underlying test execution can be shared if the traceability matrix maps each test case to both frameworks' relevant requirements, but the documentation package presented to each regulator typically needs regime-specific formatting and, in some cases, additional risk documentation unique to that jurisdiction. Confirm this mapping capability specifically during vendor selection, since building it retroactively across two regulatory frameworks is materially more expensive than designing for it from the start.

<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "FAQPage",
  "mainEntity": [
    {
      "@type": "Question",
      "name": "What makes QA \"compliance-driven\" versus standard functional testing?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Compliance-driven QA produces auditable evidence as its primary deliverable — a traceability matrix linking every requirement to test evidence, segregation of duties between developer and approver, and an immutable audit trail — rather than simply confirming the software behaves correctly. Standard functional testing optimizes for finding defects; compliance-driven QA optimizes for defensible proof of verification."
      }
    },
    {
      "@type": "Question",
      "name": "Which standards matter most when vetting a QA vendor for a regulated industry?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "It depends on your sector: medical device and health software typically need IEC 62304 and ISO 13485 fluency, pharma-adjacent systems need GxP and 21 CFR Part 11 experience, financial services need DORA and PCI-DSS awareness. Ask any vendor which of these they have direct engagement experience with rather than general familiarity, since the practical differences in documentation depth between them are significant."
      }
    },
    {
      "@type": "Question",
      "name": "How much more does compliance-grade QA cost compared to regular QA?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Expect 20-40% higher cost per test cycle once traceability maintenance, validation documentation, and segregation-of-duties overhead are priced in correctly. Vendors quoting at parity with generic QA rates are usually underpricing the documentation burden, which tends to surface later as corner-cutting under deadline pressure."
      }
    },
    {
      "@type": "Question",
      "name": "Can a small QA vendor properly implement segregation of duties?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "It is difficult below a certain team size, because segregation of duties requires enough distinct people that the same individual is not writing, testing, and approving the same work. Verify this concretely by reviewing a vendor's RACI and system access controls on a past regulated engagement rather than accepting a policy statement at face value."
      }
    },
    {
      "@type": "Question",
      "name": "What is the single biggest reason auditors reject third-party test evidence?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "The most common rejection reason is a broken or incomplete traceability link — a test case with no linked requirement, or a re-test after a code change with no updated verification record. Environment documentation gaps and unverifiable tester identity are the next most common findings in practice."
      }
    },
    {
      "@type": "Question",
      "name": "Does offshore delivery automatically disqualify a vendor from compliance-driven QA work?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "No — regulators care about evidence integrity and data handling, not the tester's physical location. What matters is a documented data processing agreement, individual non-shared credentials for every tester, and an honest answer on whether synthetic or de-identified data is used during verification testing."
      }
    },
    {
      "@type": "Question",
      "name": "What happens to test evidence produced under an earlier software safety classification if the product gets reclassified mid-engagement?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Existing evidence doesn't automatically become invalid, but it needs a documented gap analysis against the new classification's higher verification requirements, and any test that no longer meets the new depth threshold needs re-execution. A vendor's traceability tooling should flag every affected test case automatically rather than requiring a manual re-audit."
      }
    },
    {
      "@type": "Question",
      "name": "Is AI-generated test evidence acceptable to auditors in a regulated engagement?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Auditors generally accept AI-assisted test case generation as a productivity tool, but the human accountability chain still has to be intact — a qualified person must review and approve each generated test case against the linked requirement before execution, with the audit trail showing that review occurred."
      }
    },
    {
      "@type": "Question",
      "name": "Does test evidence need to be duplicated when a product must satisfy both FDA and EU MDR requirements?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Often the underlying test execution can be shared if the traceability matrix maps each test case to both frameworks' relevant requirements, but the documentation package presented to each regulator typically needs regime-specific formatting and sometimes additional risk documentation. Confirm this mapping capability during vendor selection rather than building it retroactively."
      }
    }
  ]
}
</script>
